Avid Bioservices Inc (CDMO)

[sulaco]

Sun, you're describing a Super-Avastin


Roche's Avastin,(bevacizumab) was approved by the FDA for metastatic colon cancer in 2004. Since then, it has also been approved for lung, renal, ovarian, brain (GBM), and breast cancers. The breast cancer approval was withdrawn in 2011 because OS did not improve, yet toxicities remained). It is also used for macular degeneration of the retina.

All told, Avastin (bevacizumab), bags about $3 Billion a year in profits for Roche.

If PPHM had Avastin, you'd be looking at a $20 pps plus multipliers going forward.

Chump change compared to Bavituximab. Bavi, because of its broad upstream MOA, could very well be approved in lung, breast, (unlike Avastin), liver, ano-rectal, colon, pancreas, ovarian, uterine, renal, skin, and possibly many others (e.g. thyroid, gastric, oro-pharyngeal, and testicular).

Suffice it to say, with that sort of approval profile, the pps won't be $20 plus multipliers. More like $50-100 pps plus forward P/E.

All quite possible in the next 2 years.


Best,

Joe